The rat ARF protein is translated from two closely spaced ATG start codons and can transcriptionally activate p53 in the absence of p53 protein stabilization

Cell Cycle

Volumn 5, Issue 12, 2006, Pages 1324-1330

  Hunt, Abigail E ^a,b   Moule, Madeleine G ^a,c   Fried, Mike ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ARF; ATG codon usage; p53; Transcription start sites; Translational start sites

Indexed keywords

AMINO ACID; ARF PROTEIN; CELL PROTEIN; METHIONINE; POLYCLONAL ANTIBODY; RETROVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CELL DIVISION; CODON USAGE; CONTROLLED STUDY; EXPERIMENTAL MODEL; GENE; GENETIC TRANSFECTION; HOUSEKEEPING GENE; MOUSE; MUTAGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN STABILITY; START CODON; TATA BOX; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

EID: 33745138594     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.12.2817     Document Type: Article

References (47)

1. Harris SL, Levine AJ. The p53 pathway: Positive and negative feedback loops. Oncogene 2005; 24:2899-908.
2. Prives C, Hall PA. The p53 pathway. J Pathol 1999; 187:112-26.
3. Sharpless NE, DePinho RA. p53: Good cop/bad cop. Cell 2002; 110:9-12.
4. Steele RJ, Thompson AM, Hall PA, Lane DP. The p53 tumour suppressor gene. Br J Surg 1998; 85:1460-7.
5. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-10.
6. Vousden KH, Lu X. Live or let die: The cell's response to p53. Nat Rev Cancer 2002; 2:594-604.
7. O'Shea CC, Fried M. Modulation of the ARF-p53 pathway by the small DNA tumor viruses. Cell Cycle 2005; 4:449-52.
8. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001; 2:731-7.
9. Sherr CJ. Principles of tumor suppression. Cell 2004; 116:235-46.
10. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev 1998; 12:2984-91.
11. Lomax M, Fried M. Polyoma virus disrupts ARF signaling to p53. Oncogene 2001; 20:4951-60.
12. Lowe SW. Activation of p53 by oncogenes. Endocr Relat Cancer 1999; 6:45-8.
13. Sharpless NE, DePinho RA. The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev 1999; 9:22-30.
14. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002; 2:103-12.
15. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83:993-1000.
16. Chan J, Robinson ES, Atencio J, Wang Z, Kazianis S, Coletta LD, Nairn RS, McCarrey JR. Characterization of the CDKN2A and ARF genes in UV-induced melanocytic hyperplasias and melanomas of an opossum (Monodelphis domestica). Mol Carcinog 2001; 31:16-26.
17. Di Tommaso A, Soler C, Roos C, Kitzis A, Ladeveze V. The ink4a/arf locus evolution in primates: Characterization of three ARF sequences. DNA Cell Biol 2004; 23:167-73.
18. Kim SH, Mitchell M, Fujii H, Llanos S, Peters G. Absence of p16INK4a and truncation of ARF tumor suppressors in chickens. Proc Natl Acad Sci USA 2003; 100:211-6.
19. Gilley J, Fried M. One INK4 gene and no ARF at the Fugu equivalent of the human INK4A/ARF/INK4B tumour suppressor locus. Oncogene 2001; 20:7447-52.
20. Kozak M. A short leader sequence impairs the fidelity of initiation by eukaryotic ribosomes. Gene Expr 1991; 1:111-5.
21. Kozak M. Structural features in eukaryotic mRNAs that modulate the initiation of translation. J Biol Chem 1991; 266:19867-70.
22. Kozak M. Regulation of translation via mRNA structure in prokaryotes and eukaryotes. Gene 2005.
23. Moule MG, Collins CH, McCormick F, Fried M. Role for PP2A in ARF signaling to p53. Proc Natl Acad Sci USA 2004; 101:14063-6.
24. Mor O, Read M, Fried M. p53 in polyoma virus transformed REF52 cells. Oncogene 1997; 15:3113-9.
25. Swafford DS, Middleton SK, Palmisano WA, Nikula KJ, Tesfaigzi J, Baylin SB, Herman JG, Belinsky SA. Frequent aberrant methylation of p16INK4a in primary rat lung tumors. Mol Cell Biol 1997; 17:1366-74.
26. Rodriguez-Viciana P, Collins CH, Moule MG, Fried M. Chromosomal instability at a mutational hotspot in polyoma middle T-antigen affects its ability to activate the ARF-p53 tumor suppressor pathway. Oncogene 2005.
27. Hupp TR, Sparks A, Lane DP. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 1995; 83:237-45.
28. Korgaonkar C, Zhao L, Modestou M, Quelle DE. ARF function does not require p53 stabilization or Mdm2 relocalization. Mol Cell Biol 2002; 22:196-206.
29. Woo RA, McLure KG, Lees-Miller SP, Rancourt DE, Lee PW. DNA-dependent protein kinase acts upstream of p53 in response to DNA damage. Nature 1998; 394:700-4.
30. Carnero A, Hudson JD, Price CM, Beach DH. p16INK4A and p19ARF act in overlapping pathways in cellular immortalization [see comments]. Nat Cell Biol 2000; 2:148-55.
31. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997; 91:649-59.
32. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999; 13:2658-69.
33. Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel MF, Sherr CJ, Zambetti GP. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev 2000; 14:2358-65.
34. Aslanian A, Iaquinta PJ, Verona R, Lees JA. Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics. Genes Dev 2004; 18:1413-22.
35. Datta A, Nag A, Raychaudhuri P. Differential regulation of E2F1, DP1, and the E2F1/DP1 complex by ARF. Mol Cell Biol 2002; 22:8398-408.
36. Datta A, Nag A, Pan W, Hay N, Gartel AL, Colamonici O, Mori Y, Raychaudhuri P. Myc-ARF (alternate reading frame) interaction inhibits the functions of Myc. J Biol Chem 2004; 279:36698-707.
37. Eymin B, Karayan L, Seite P, Brambilla C, Brambilla E, Larsen CJ, Gazzeri S. Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene 2001; 20:1033-41.
38. Kuo ML, Duncavage EJ, Mathew R, den Besten W, Pei D, Naeve D, Yamamoto T, Cheng C, Sherr CJ, Roussel MF. Arf induces p53-dependent and -independent antiproliferative genes. Cancer Res 2003; 63:1046-53.
39. Martelli F, Hamilton T, Silver DP, Sharpless NE, Bardeesy N, Rokas M, DePinho RA, Livingston DM, Grossman SR. p19ARF targets certain E2F species for degradation. Proc Natl Acad Sci USA 2001; 98:4455-60.
40. Qi Y, Gregory MA, Li Z, Brousal JP, West K, Hann SR. p19ARF directly and differentially controls the functions of c-Myc independently of p53. Nature 2004; 431:712-7.
41. Rocha S, Campbell KJ, Perkins ND. p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor. Mol Cell 2003; 12:15-25.
42. Chen L, Chen J. MDM2-ARF complex regulates p53 sumoylation. Oncogene 2003; 22:5348-57.
43. Rizos H, Darmanian AP, Indsto JO, Shannon JA, Kefford RF, Mann GJ. Multiple abnormalities of the p16INK4a-pRb regulatory pathway in cultured melanoma cells. Melanoma Res 1999; 9:10-9.
44. Tago K, Chiocca S, Sherr CJ. Sumoylation induced by the Arf tumor suppressor: A p53-independent function. Proc Natl Acad Sci USA 2005; 102:7689-94.
45. Woods YL, Xirodimas DP, Prescott AR, Sparks A, Lane DP, Saville MK. p14 Arf promotes small ubiquitin-like modifier conjugation of Werners helicase. J Biol Chem 2004; 279:50157-66.
46. Xirodimas DP, Chisholm J, Desterro JM, Lane DP, Hay RT. P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2. FEBS Lett 2002; 528:207-11.
47. Sugimoto M, Kuo ML, Roussel MF, Sherr CJ. Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol Cell 2003; 11:415-24.